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Abstract 
A high performance liquid chromatography method with tandem mass 
spectrometry detection is described for the determination of paroxetine, an 
antidepressant drug, and its metabolite (3S, 4R)-4-(4-fluorophenyl)-3-(4-hydroxy-
3-methoxyphenoxymethyl) piperidine (HM paroxetine) in human plasma. Plasma 
samples were hydrolyzed with hydrochloric acid and then analytes were extracted 
with ethyl acetate at alkaline pH. Extracts were analysed by high performance 
liquid chromatography coupled to an atmospheric pressure ionisation-electrospray 
(ESI) interface and an ion trap mass spectrometer. Chromatography was 
performed on a reversed-phase column using acetonitrile/0.02% formic acid 
(66:34, v/v) as a mobile phase. The mass spectrometer was operated in the 
multiple reaction monitoring mode. The method was validated over a 
concentration range of 0.75-100 µg/L and 5-100 µg/L for paroxetine and HM 
paroxetine, respectively. Mean recoveries of 77% for paroxetine and 76% for HM 
paroxetine were found, with precision always better than 15%. The limits of 
detection and quantification were 0.20 and 0.70 µg/L for paroxetine, and 0.70 and 
2.20 µg/L for its metabolite. The method was applied to the analysis of plasma 
samples obtained from nine healthy male volunteers administered with a single 
oral dose of 20 mg paroxetine. After the 20 mg-dose, the mean peak plasma 
concentration was 8.60 µg/L for paroxetine and 92.40 µg/L for HM paroxetine 
showing a tenfold-ratio between the metabolite and the parent drug along the 
entire time-concentration curve. 
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Introduction 
 Paroxetine, (3S, 4R)-(4-(4-fluorophenyl)-3-(3,4-
methylenedioxyphenoxymethyl)piperidine), is an antidepressant which acts as a potent 
selective serotonine re-uptake inhibitor (SSRI) in the central nervous system.1 It has 
been successfully used worldwide for the treatment of a variety of depression, 
obsessive-compulsive and panic states and other psychiatric disorders.2,3
 In humans, paroxetine is initially O-demethylenated by CYP2D6, an isoenzyme 
of cytochrome P450 giving rise to an unstable catechol ((3S, 4R)-4-(4-fluorophenyl)-3-
(3,4-dihydroxyphenoxymethyl)piperidine) which is then methylated in the C3 or C4 
positions of the benzene ring. A minor metabolic pathway of the catechol metabolite 
has also been described leading to the formation of the (3S, 4R)-4-(4-fluorophenyl)-3-
(hydroxymethyl)piperidine metabolite.3-6 The methylation of catechol is putatively 
catalyzed by catechol-O-methyltransferase (COMT) and the predominant metabolite 
resulting from this O-methylation is (3S, 4R)-4-(4-fluorophenyl)-3-(4-hydroxy-3-
methoxyphenoxymethyl)piperidine (HM paroxetine). This major metabolite was 
isolated from human urine and identified by mass spectrometry as conjugated to 
glucuronic acid and sulphate.7
 Paroxetine metabolites have been reported to be pharmacologically inactive in 
vitro and ex-vivo and they are not likely to contribute to the clinical effects of 
paroxetine.1,2,5,8 Metabolites have been described to appear in plasma simultaneously 
with paroxetine, suggesting a first-pass metabolism.3,6  Non-linear pharmacokinetics 
behaviour has been described for paroxetine.5,6,9
 Pharmacokinetic properties of paroxetine in healthy volunteers have been 
characterized following both single and multiple oral doses in several studies.3,5,6,10 
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However, although paroxetine metabolites have been described in preliminary reports 
and HM paroxetine has been always reported as a major metabolite6,7, to our knowledge 
its pharmacokinetic properties in humans have never been reported in peer reviewed 
scientific journals. Moreover, the only attempt to detect HM paroxetine in plasma 
samples involved the determination of its free form;10 in the event, HM paroxetine was 
only found in one patient over a series of seven after repeated doses. 
 This paper reports an analytical method to determine paroxetine and its main 
metabolite HM paroxetine in plasma samples after acid hydrolysis. After a liquid–liquid 
extraction with ethyl acetate, high performance liquid chromatography-electrospray ion 
trap mass spectrometry (LC/MS/MS) was employed to quantify the analytes by 
monitoring their precursor-product ion combinations in the multiple-reaction 
monitoring (MRM) mode. The method was developed to support pharmacokinetic 
studies in healthy volunteers following administration of a clinical dose (20 mg) of 
paroxetine.  
 
EXPERIMENTAL 
Materials  
 Paroxetine, (3S,4R)-(4-(4-fluorophenyl)-3-(3,4-
methylenedioxyphenoxymethyl)piperidine), and HM paroxetine, ((3S,4R)-4-(4-
fluorophenyl)-3-(4-hydroxy-3-methoxyphenoxymethyl)piperidine), were synthesized in 
the “Centro de Investigación y Desarrollo of Centro Superior de Investigaciones 
Científicas” (CID-CSIC, Barcelona, Spain). Details of the preparation of standards are 
described elsewhere.11 Pholedrine (4-hidroxy-N,α-dimethylphenethylamine) was kindly 
donated by the Deutsche Sporthochschule, Biochemistry Department (Cologne, 
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Germany). Methoxyphenamine (2-methoxy-N,α-dimethylphenethylamine) and 
sulfatase type H-1 from Helix Pomatia (14,600 units/g) were supplied by Sigma (St. 
Louis, MO, USA). β-Glucuronidase from E. Coli K12 (200 units/mL) was obtained 
from Roche (Manheim, Germany). Ultrapure water was obtained using a Milli-Q 
purification system (Millipore, Molsheim, France). HPLC-grade acetonitrile, ethyl 
acetate, hydrochloric acid (37%), formic acid (85%), and sodium hydroxide were 
obtained from Merck (Darmstadt, Germany). A pool of blank plasma samples was 
supplied by the blood bank of Hospital del Mar, Barcelona, Spain.  
Human subjects, clinical protocol, and blood and urine sampling 
Samples were obtained from 9 healthy male subjects (mean [SD] age: 23.1 [2.0] 
years; mean [SD] weight: 67.2 [9.3] kg; mean [SD] height: 173.3 [3.7] cm), who were 
given a single 20 mg oral dose of paroxetine (Seroxat, GSK, Spain). The study protocol 
was approved by the local ethical committee (CEIC-IMAS) and by the Spanish Ministry 
of Health.  
 The drug was administered at 9.00 a.m. to the subjects in a fasting state. Blood 
samples were obtained through a catheter inserted into a peripheral vein before (0 h) and 
at 1, 3, 5, 8 and 24 h after drug administration. Blood was collected in heparinized 
tubes. Within 30 minutes after drawing, samples were centrifuged at 1100 g and 4ºC for 
10 minutes, and plasma was stored at –20ºC until analysis. Urine was also collected at 
different time periods from all volunteers: 0-3 h, 3-6 h, 6-9h, 9-12h, 12-24 h.  
 Subjects were phenotyped for CYP2D6 activity using dextromethorphan as drug 
probe. The dextromethorphan/dextrorphan urinary metabolic ratio12 was used to classify 
subjects as extensive or poor metabolizers. All participants were extensive metabolizers. 
Instrumentation 
 5
 Liquid chromatography.  Analyses were performed using a HP 1050 liquid 
chromatograph (Agilent, Palo Alto, CA, USA). The column used was a Synergi 4u 
MAX-RP 80A (150 x 2 mm x 4µm; Phenomenex, Aschaffenburg, Germany). Isocratic 
chromatography was conducted at room temperature with a mobile phase consisting of 
acetonitrile/0.02% formic acid (66:34, v/v) at a flow rate of 0.25 mL/min. All 
chromatographic solvents were degassed with helium before use. The injection volume 
was 10 µL. The dead time of the column, t0, was determined by injection of methanol. 
 Mass spectrometry.  All experiments were performed using an Esquire 3000 ion 
trap mass spectrometer (Bruker Daltonics, Bremen ,Germany) equipped with an 
atmospheric pressure ionisation-electrospray (ESI) interface. Experiments were run 
using positive electrospray ionisation mode. The following ESI conditions were applied: 
drying gas (nitrogen) heated to 325°C at flow rate of 8 L/min; the pressure of nebulizer 
gas (nitrogen) was 30 psi. The Esquire LC/MS/MS ion trap mass spectrometer was 
operated at unit resolution in the multiple reaction monitoring (MRM) mode. The 
instrument parameters were individually optimised to maximize the signal for the 
transition of the selected precursor ion to the most abundant product ion for each 
compound by infusing a constant flow of a solution of each drug dissolved in mobile 
phase. The fragmentation channels monitored for [M+H]+ to product ions were m/z 
330.1→191.8 for paroxetine, m/z 179.8→148.8 for methoxyphenamine (I.S.), m/z 
332.1→191.8 for HM paroxetine, and m/z 165.8→134.8 for pholedrine (I.S.). Taking 
into account the differences of ion trap parameters optimized for each compound, 
samples were processed with two different ion trap methods in order to obtain the best 
sensitivity. Maximum MRM dwell times were 70 and 100 ms for paroxetine and HM 
paroxetine, respectively. Fragmentation was induced with resonant excitation amplitude 
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of 0.85 V for paroxetine, 0.65 V for methoxyphenamine (I.S.), 0.9 V for HM paroxetine 
and 0.7 V for pholedrine (I.S.), following isolation of the ion over a selected mass 
window.  
 Working standards.  Stock standard solutions (1g/L) of paroxetine, HM 
paroxetine, methoxyphenamine and pholedrine were prepared in methanol. Working 
solutions at concentrations of 10, 1, 0.1 mg/L were prepared by dilution of the stock 
standard solutions with methanol, and were stored at –20ºC until analysis.  
 Preparation of calibration and quality control samples.  Calibration standards 
containing 0.75, 3, 10, 25, 50, 100 µg/L of paroxetine and 5, 10, 25, 50, 100 µg/L of 
HM paroxetine were prepared in duplicate daily for each analytical batch by adding 
suitable amounts of methanol working solutions to 1 mL of a pre-checked drug-free 
plasma pool. At the beginning of the study, quality control samples of 80 µg/L (high 
control), 40 µg/L (medium control) and 4 µg/L (low control) for paroxetine and 6 µg/L 
(low control) for HM paroxetine were prepared once, aliquoted and stored at –20ºC. 
They were included in each analytical batch to control the daily quality of the analytical 
process and to check the stability of samples under storage conditions. No calibration 
standards or quality control samples were prepared for urine samples as only qualitative 
analysis was performed to investigate HM paroxetine conjugation. 
 Protocol for preparation of plasma samples.  One mL of plasma was transferred 
into 15-mL screw-capped glass tubes and 30 µL of methoxyphenamine (1 mg/L) and 30 
µL of pholedrine (1 mg/L) in methanol were added. Acidic hydrolysis was performed 
by adding 1 mL of 0.5 M hydrochloric acid. Samples were incubated for 30 min at 
100°C and then cooled at room temperature. After hydrolysis, plasma samples were 
adjusted to pH 12 with NaOH (10 M) and extracted with 5 mL ethyl acetate. Samples 
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were centrifuged 10 min at 3500 rpm and the organic phase was evaporated to dryness. 
The dried extracts were reconstituted in 200 µL of mobile phase by vigorous vortex 
mixing and transferred into 200 µL injection vials. Volumes of 10 µL were injected into 
the chromatographic system. 
Protocol for urine hydrolysis and sample preparation.  The 0-3 h urine sample 
from one volunteer was used to perform several experiments of acid and enzymatic 
hydrolysis. Four aliquots of one ml of urine (diluted 1:5 with ultrapure water) were 
transferred into 15-mL screw-capped glass tubes and 30 µL of methoxyphenamine (1 
mg/L) and 30 µL of pholedrine (1 mg/L) in methanol were added. The following 
procedures were applied: 
- one aliquot of urine was extracted without applying any hydrolysis procedure; 
- one aliquot of urine underwent an acidic hydrolysis as described for plasma 
samples; 
- one aliquot of urine underwent an enzymatic hydrolysis with sulfatase (1 
mg/mL) in one mL 0.1 M sodium acetate buffer, pH 5.2, 3h at 55ºC; 
- one aliquot of urine underwent an enzymatic hydrolysis with glucuronidase (30 
µL β-glucuronidase in one mL 0.2M sodium phosphate buffer, pH 7.0) for 3h at 
55ºC. 
After incubation, samples were cooled at room temperature, adjusted to pH 12 with 
NaOH (10 M) and extracted as described for plasma samples. Extracted urine samples 
were analyzed by LC/MS/MS with the same conditions as those used for plasma 
samples. Aliquots of drug-free urine underwent the same hydrolysis treatments and 
were used to verify absence of chromatographic interferences. All the experiments were 
carried out in duplicate. 
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 Validation procedure.  Prior to the application to real plasma samples, the 
method was tested following a 3-day validation protocol. Selectivity, recovery, 
linearity, stability, precision, accuracy, and limits of detection and quantification were 
assayed. 
The selectivity of the method was studied by analysing several plasma samples 
(n=7) and checking for the presence of interfering substances at the appropriate MRM 
transition. Calibration curves were tested over the ranges 0.75-100 µg/L paroxetine and 
5-100 µg/L HM paroxetine. Peak area ratios between compounds and I.S. were used for 
calculations. A weighted (1/concentration) least-squares regression analysis was used 
(SPSS, version 9.0.2 for Windows). Four replicates were analysed at the following 
concentrations: 0.75, 3, 10, 25, 50 and 100 µg/L for paroxetine, and 5, 10, 25, 50 and 
100 µg/L for HM paroxetine.  
Signal-to-noise ratios of 3 and 10 were used for estimating the limits of detection 
and quantification, respectively. The quantification limits were verified by the analysis 
of five samples prepared at the respective quantification limits estimated as described. 
Analytical recoveries were calculated by comparing the peak areas obtained when 
calibration samples were analysed by adding the reference substances and the internal 
standards prior to and after the extraction procedure in the drug-free plasma and in the 
extract from drug-free plasma, respectively. The recoveries were assessed at three 
concentration levels using four replicates at each level (3, 25 and 100 µg/L) for 
paroxetine and (5, 25 and 100 µg/L) for HM paroxetine and twelve replicates for both 
I.S. at a concentration of 30 µg/L.  
Three replicates of quality control samples at three different concentrations of 
paroxetine (4, 40 and 80 µg/L) and HM paroxetine (6, 40 and 80 µg/L) added to drug-
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free plasma samples were extracted as reported above and analysed for the 
determination of intra-assay precision and accuracy. The inter-assay precision and 
accuracy were determined for three independent experimental assays of the 
aforementioned replicates. Inter and intra-assay precision were expressed as the relative 
SD (RSD) of concentrations calculated for quality control samples. Inter and intra-assay 
accuracy were expressed as the mean of the absolute value of the relative error of the 
calculated concentrations.  
The stability of paroxetine and its metabolite in plasma was evaluated under 
three freeze/thaw cycles. The test involved a comparison of replicate stability samples, 
which had been frozen and thawed three times with a fresh plasma sample that had been 
thawed only once. 
Data Analysis.  Pharmacokinetic parameters, Cmax (µg/L), Tmax (h), Ke (h-1), T1/2 
(h), and AUC (0-24h) (µg/L.h) were determined using the PK Functions for Microsoft 
Excel computer program.13
 
RESULTS AND DISCUSSION 
Validation results 
The full scan MS/MS spectra as well as the proposed fragmentation patterns for 
paroxetine, HM paroxetine, methoxyphenamine and pholedrine, are shown in Figure 1. 
Selected reaction monitoring (SRM) chromatograms are depicted in Figures 2 and 3. 
Dead time (t0) of the column was 0.5 min and the compounds showed similar retention 
times (about 1.5 min) but could be identified without interference due to the different 
SRM channels for each. The studied compounds as well as the internal standards 
formed protonated molecules ([M+H+]) in the ion source, and the selectivity of the 
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MRM approach led to clean chromatograms free of background interference (see 
Figures 2A and 3A for data for blank plasma).  
The recoveries (mean + SD) obtained were 77.3 + 3.7 % for paroxetine, 76.1 + 
11.5 % for HM paroxetine, 88.6 + 10.9% for methoxyphenamine and 67.4 + 8.1% for 
pholedrine. Calibration curves (area ratio to the respective I.S.) were linear in the 
concentration range tested for paroxetine and HM paroxetine, with coefficients of 
determination (r2) higher than 0.99 in all cases.  
Tables 1 and 2 show the results obtained for intra-assay and inter-assay precision 
and accuracy for paroxetine and HM paroxetine. These results satisfactorily met 
internationally established acceptance criteria.14 Estimated limits of detection and 
quantification were 0.20 and 0.70 µg/L for paroxetine, and 0.70 and 2.20 µg/L for HM 
paroxetine. In the case of analysis, in three samples out of nine at 1h after 
administration, the drug was detected but could not be quantified. On the other hand, 
samples which had a concentration higher than 100 µg/L of HM paroxetine were diluted 
with ultrapure water to fit within the working range, and were reanalysed using the 
same sample preparation procedure described above. 
The freeze-thaw stability test showed that paroxetine and its metabolite (HM 
paroxetine) in human plasma were stable for at least three freeze-thaw cycles (data not 
shown). Moreover, the stability of HM paroxetine under the hydrolysis conditions was 
established when analytical recoveries were calculated by comparing the peak areas 
obtained when calibration samples were analysed by adding the reference substance and 
the internal standards both prior to and after the extraction procedure. HM paroxetine 
was stable under acidic hydrolysis conditions, as good responses were obtained from 
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calibration samples when HM paroxetine and the internal standard had been added prior 
to the extraction procedure. 
Because deuterated analogues of paroxetine were not commercially available, it 
was necessary to find an alternative internal standard. Methoxyphenamine has proven to 
be a good choice because it shares several physicochemical properties with paroxetine, 
making it suitable for this type of analysis. Our previous experience with the analysis of 
drugs bearing a 4-hydroxy-3-methoxy grouping like HMMA (4-hydroxy-3-methoxy-
methamphetamine)15, using pholedrine as internal standard, showed good results and 
therefore it was selected for the analysis of HM paroxetine in the present study.  
 The analytical method presented here for the simultaneous determination of 
paroxetine and HM paroxetine from plasma samples has demonstrated enough 
sensitivity, specificity and selectivity for the purposes of the present study. High-
performance liquid chromatography (HPLC) with ultaviolet (UV), fluorescence or 
coulometric detection was utilized in previously published analytical methods.16-24 
However, these detectors were not sufficiently specific and sensitive for the 
determination of paroxetine, and required laborious and time-consuming sample pre-
treatment to remove interfering substances and/or the formation of derivates before 
HPLC analysis. Recently a LC/MS/MS method for paroxetine determination in plasma 
has been reported.25 However, this method does not include the analysis of its main 
metabolite.  
 Despite the extensive number of assay procedures for the determination of 
paroxetine published up to now16-27, only two studies describe the simultaneous 
determination of paroxetine and its metabolite HM paroxetine in plasma.10,24 
Kristoffersen et al.24 provided detection limits around 0.025 µmol/L (8 µg/L) for 
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paroxetine and 0.12 µmol/L (40 µg/L) for HM paroxetine, which are of use in cases of 
acute intoxication but are not suitable for the purposes of a pharmacokinetic study in 
which a single dose of 20 mg is administered and lower concentrations are expected for 
the parent drug and its metabolite. However, results obtained for real cases of acute 
paroxetine intoxications were not reported, and it is unknown if the method, as it was 
described24, is able to detect HM paroxetine in clinical samples. On the other hand, 
Härtter et al.10 described a method for paroxetine and its main metabolite for application 
in pharmacokinetic studies; HM paroxetine was detected in some samples but could not 
be quantified. Our previous experience with drugs bearing a methylene-dioxy grouping 
like MDMA (3,4-methylendioxymethamphetamine)28 showed that the corresponding 
hydroxy-methoxy metabolite, HMMA (3-hydroxy-4-methoxy-methamphetamine), is 
extensively conjugated and that despite very sensitive assays this metabolite in its free 
form was not quantifiable. This observation oriented the method development towards 
the introduction of a hydrolysis step in the sample preparation procedure. The kinetics 
of HM paroxetine in plasma and urine samples has never been reported, but some 
studies from the pharmaceutical company that developed the drug suggest that this 
metabolite is mainly excreted as a conjugate.6,7  
 
Application to pharmacokinetic study 
Figure 4 represents time courses of paroxetine and HM paroxetine plasma 
concentrations, following a single oral dose of 20 mg paroxetine to each of 9 healthy 
volunteers. The median Tmax of paroxetine (5 hours) was slightly shifted with respect to 
that of HM paroxetine (3 hours). HM paroxetine concentrations were one order of 
magnitude higher than those observed for the parent drug along the 24 hour time course. 
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Inter-subject variabilities of 1:10 and 1:5 were observed in the cases of paroxetine 
(range 1.6-15.7 µg/L at C max) and HM paroxetine (range 33.8-145.7 µg/L at C max) 
concentrations along the time course of the experimental session. The pharmacokinetic 
parameters calculated for paroxetine and HM paroxetine are reported in Table 3. 
Paroxetine was identified in both hydrolysed and non-hydrolysed urine samples. 
In contrast, HM paroxetine could not be identified in non-hydrolysed samples, while it 
was always present in hydrolysed urine, independently from the hydrolysis procedure 
applied. This observation confirms early results that HM paroxetine is presented in 
biological fluids mainly as the sulfate and the glucuronoconjugate.6,7
 Pharmacokinetic parameters obtained here for paroxetine are in agreement with 
previously published data.2,6,29 Concerning HM paroxetine, this is the first time that this 
metabolite has been determined. The fact that the Tmax of HM paroxetine precedes 
marginally that corresponding to paroxetine (3 h vs. 5 h), combined with the high HM 
paroxetine plasma concentrations, support a strong first-pass metabolism and may 
explian the inter-subject variabilities observed among the 9 healthy volunteers 
participating in the study (Figure 4).  
 It is worth noting that, when Härtter et al.10 analysed HM paroxetine without any 
hydrolysis step, this metabolite was hardly found in plasma samples of volunteers also 
administered 20 mg of paroxetine, and the reported limit of detection for HM paroxetine 
was 5 μg/L. If this figure is compared with the encountered concentrations of HM 
paroxetine (sum of its conjugated and unconjugated form) (Cmax 92.40 µg/L), it can be 
estimated that HM paroxetine is conjugated in plasma to an extent most probably higher 
than 95%. This hypothesis is confirmed from results observed in urine samples. Indeed 
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HM paroxetine could not be found in non-hydrolysed urine, while it was observed after 
acidic and enzymatic hydrolysis with glucuronidase and sulfatase. 
 The simultaneous determination of paroxetine and HM paroxetine is expected to 
provide some insight into the non-linear kinetics reported for paroxetine after repeated 
doses.5,6,9  
 During metabolism, the methylation of the unstable catechol metabolite (3S, 
4R)-4-(4-fluorophenyl)-3-(3,4-dihydroxyphenoxymethyl)piperidine, putative 
intermediate of HM paroxetine, by catechol O-methyltransferase (COMT) may give rise 
to two metabolites (3S, 4R)-4-(4-fluorophenyl)-3-(4-hydroxy-3-
methoxyphenoxymethyl)piperidine (HM paroxetine) and (3S, 4R)-4-(4-fluorophenyl)-
3-(3-hydroxy-4-methoxyphenoxymethyl)piperidine. These differ only in the 
methylation position but share the same fragmentation pattern with the same most 
intense MS/MS transition (m/z 332.0→191.8). The possibility of a co-analysis of both 
metabolites should be considered. However, many reports5,7,10 suggest that methylation 
at the C3 position (HM paroxetine) is the predominant paroxetine pathway and, 
moreover, it is known that COMT prefentially alkylates compounds containing phenol 
moieties at the 3 position, and to a much lesser extent at position 4.30 If a co-analysis 
method were available, it is highly likely that concentrations of the metabolite 
methylated at C4 would be much lower in comparison with that of HM paroxetine. 
 
CONCLUSIONS 
In conclusion, the LC/MS/MS method presented here for the simultaneous 
determination of paroxetine and HM paroxetine requires only a one-step extraction with 
ethyl acetate for plasma samples prior to isocratic chromatography, which enables a 
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rapid and simple assay when compared to previous published methods. In addition, 
MS/MS detection gives adequate specificity for routine monitoring of therapeutic drug 
administration. With this new method the levels of paroxetine and its metabolite could 
be measured for up to 24 hours in plasma samples of 9 volunteers administered 20 mg 
paroxetine. HM paroxetine plasma concentrations are one order of magnitude higher 
than those observed for the parent drug for the entire 24 hour time course. This 
metabolite is present in biological specimens as the glucuronoconjugate and sulfate 
conjugate. 
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Figure legends: 
Figure 1. Full scan MS/MS spectra and the proposed patterns of fragmentation for 
(A) paroxetine, (B) HM paroxetine, (C) methoxyphenamine and (D) pholedrine. 
 
Figure 2. LC/MS/MS chromatograms of (A) blank human plasma, (B) human 
plasma spiked with 3 µg/L of paroxetine and 30 µg/L of I.S., (C) plasma sample 
from a dosed volunteer containing 9 µg/L of paroxetine. 
 
Figure 3. LC/MS/MS chromatograms of (A) blank human plasma, (B) human 
plasma spiked with 5 µg/L of HM paroxetine and 30 µg/L of I.S., (C) plasma 
sample from a dosed volunteer containing 28 µg/L of HM paroxetine. 
  
Figure 4. Plasma concentration versus time for (A) paroxetine, (B) HM paroxetine 
and (C) the mean profile from 9 healthy volunteers following the administration of 
20 mg paroxetine.  
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Table 1 
Intra-day precision and accuracy obtained for paroxetine and HM paroxetine in plasma. 
Compound Concentration 
(µg/L) 
Number of 
observations 
Estimated 
mean ± SD 
(µg/L) 
Precision 
(R.S.D) 
Accuracy
(Error %)
 4 3 3.50 ± 0.10 0.6 12.9 
Paroxetine 40 3 36.30 ± 2.40 6.5 9.2 
 80 3 76.10 ± 8.50 11.1 8.4 
 6 3 5.2 ± 0.60 11.0 13.8 
HM paroxetine 40 3 43.90  ± 3.40 7.7 9.8 
 80 3 91.40 ± 11.10 12.2 14.2 
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 Table 2 
Intermediate precision and accuracy obtained for paroxetine and HM paroxetine in 
plasma. 
Compound Concentration 
(µg/L) 
Number of 
observations 
Estimated 
mean ± SD 
(µg/L) 
Precision 
(R.S.D) 
Accuracy
(Error %)
 4 9 3.70 ± 0.50 14.9 13.3 
Paroxetine 40 9 40.10 ± 4.90 12.1 10.1 
 80 9 82.90 ± 7.70 9.3 8.5 
 6 9 5.90 ± 0.90 14.6 11.7 
HM paroxetine 40 9 43.80 ± 5.00 11.4 13.6 
 80 9 90.20 ± 10.60 11.8 13.1 
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Table 3  
Pharmacokinetic parameters for paroxetine and HM paroxetine (mean ± SD, n=9) 
 
Compound Paroxetine HM paroxetine 
Cmax (µg/L) 8.60 ± 5.50 92.40 ± 39.60 
Tmax (h)a 5 (3-5) 3 (3-5) 
Ke (h-1) 0.080 ± 0.013 0.096 ± 0.026 
T1/2 (h) 8.80 ± 1.50 7.80 ± 2.40 
AUC (0-24h) (µg/L.h) 96.50 ± 65.90 988.10 ± 467.80 
a  Expressed as a median (range).
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